Safety and Tolerability of a 'Refrigeration-free' Formulation of Interferon Beta-1b – Results of a Double-blind, Multicentre, Comparative Study in Patients with Relapsing–Remitting or Secondary Progressive Multiple Sclerosis

Author： Baum K    

Publisher： Field House Publishing

ISSN： 0300-0605

Source： The Journal of International Medical Research, Vol.34, Iss.1, 2006-01, pp. : 1-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Interferon- -1b: A Review of its Use in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis

By McCormack P.L.   Scott L.J.  

CNS Drugs, Vol. 18, Iss. 8, 2004-01 ,pp. : 521-546

Adis International

Access to resources Recommend Favorite

A Population Approach to Characterize Interferon Beta‐1b Effect on Contrast Enhancing Lesions in Patients With Relapsing Remitting Multiple Sclerosis

By  

Cpt: Pharmacometrics & Systems Pharmacology, Vol. 4, Iss. 5, 2015-05 ,pp. : 295-304

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long-Term Cost Effectiveness of Interferon- -1a in the Treatment of Relapsing-Remitting Multiple Sclerosis: An Econometric Model

By Lepen C.  

Clinical Drug Investigation, Vol. 23, Iss. 9, 2003-01 ,pp. : 571-581

Adis International

Access to resources Recommend Favorite

Subcutaneous Recombinant Interferon- -1a (Rebif®): A Review of its Use in Relapsing-Remitting Multiple Sclerosis

By Murdoch David   Lyseng-Williamson Katherine A.  

Drugs, Vol. 65, Iss. 9, 2005-01 ,pp. : 1295-1312

Adis International

Access to resources Recommend Favorite

Comparative Assessment of Immunomodulating Therapies for Relapsing-Remitting Multiple Sclerosis

By Khan O.   Zabad R.   Caon C.   Zvartau-Hind M.   Tselis A.   Lisak R.  

CNS Drugs, Vol. 16, Iss. 8, 2002-01 ,pp. : 563-578

Adis International

Access to resources Recommend Favorite